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Abstract
The live attenuated vaccine (LAV) SIVmac239Δnef (SIVΔnef) confers the best protection
among all the vaccine modalities tested in rhesus macaque model of HIV-1 infection. This
vaccine has a unique feature of time-dependent protection: macaques are not protected at
3–5 weeks post vaccination (WPV), whereas immune protection emerges between 15 and
20 WPV. Although the exact mechanisms of the time-dependent protection remain incom-
pletely understood, studies suggested that both cellular and humoral immunities contribute
to this time-dependent protection. To further elucidate the mechanisms of protection
induced by SIVΔnef, we longitudinally compared the global gene expression profiles of SIV
Gag-CM9+ CD8+ (Gag-specific CD8+) T cells from peripheral blood of Mamu-A*01+ rhe-
sus macaques at 3 and 20 WPV using rhesus microarray. We found that gene expression
profiles of Gag-specific CD8+ T cells at 20 WPV are qualitatively different from those at 3
WPV. At 20 WPV, the most significant transcriptional changes of Gag-specific CD8+ T cells
were genes involved in TCR signaling, differentiation and maturation toward central memory
cells, with increased expression of CCR7, TCRα, TCRβ, CD28 and decreased expression
of CTLA-4, IFN-γ, RANTES, granzyme A and B. Our study suggests that a higher quality of
SIV-specific CD8+ T cells elicited by SIVΔnef over time contributes to the maturation of
time-dependent protection.
Introduction
A safe and effective prophylactic vaccine is an ultimate solution to human immunodeficiency
virus type 1 (HIV-1) pandemic; however, it remains elusive after 3 decades of extensive
research. Among all the vaccine modalities tested in rhesus macaque/SIV model for HIV-1
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vaccine study, SIVmac239 with nef gene deletion (SIVΔnef), a live attenuated vaccine (LAV),
induces the most potent protection against pathogenic SIV challenges via intravenous or
mucosal routes [1, 2]. It achieved 93% (59/63) protection in vaccinated macaques [3]. Despite
the potent protection induced by SIVΔnef LAV, it was revealed that the pathogenicity in neo-
natal macaques after infection with SIVΔ3, a LAV with deletion in nef, vpr and LTR regions
[4], manifested with high viremia and AIDS development. A prolonged follow-up study in
adult macaques also showed that most macaques vaccinated with SIVΔ3 LAV had immune
dysregulation, and 18% (2/11) developed AIDS [5]. Although the potential risks of inducing
immune dysregulation and even AIDS preclude HIV-1 LAV for human use, a better under-
standing of the underlying mechanisms of potent protection induced by SIVΔnef LAV may
facilitate development of safe HIV-1 vaccines with improved efficacy.
The protection induced by SIVΔnef LAV shows a unique time-dependent pattern. SIVΔnef
replicates efficiently in rhesus macaques after vaccination. Plasma viral load peaks at 7–12 days
post-inoculation, but drastically declines to undetectable levels at 5 weeks post-vaccination
(WPV) [6]. There is no or very limited protection against intravenous challenge with patho-
genic wild-type SIVmac251 at 5 WPV, but potent protection arises at 15 WPV and thereafter
[6]. The prolonged delay of emergence of protection against subsequent SIV challenge after
SIVΔnef LAV indicates there is an immune maturation over time [6–8]. It has been shown
that the time-dependent protection induced by SIVΔnef LAV is associated with vigorous SIV-
specific CD8+ T cell responses [2, 9–12], but not neutralizing antibodies [2, 13]. In our recent
studies, we found that IgG antibodies specific to SIV gp41 trimers with limited neutralizing
activities correlated spatially and temporally with the maturation of local protection against
high-dose pathogenic SIV vaginal challenge [14], but SIV-specific CD8+ T cells quantitatively
did not correlate with maturation of vaginal protection [15, 16]. However, after SIVΔnef vacci-
nation, the transcription factor profiles of SIV-specific CD8+ T cells in peripheral blood
changed over time and temporally associated with the protection, indicating SIV-specific
CD8+ T cells elicited by SIVΔnef are qualitatively different between time points of un-protec-
tion and protection [17].
To further elucidate the mechanisms of protection induced by SIVΔnef vaccine, in this
study, we longitudinally compared the global gene expression profiles of SIV Gag-specific
CD8+ T cells targeting a dominant protective epitope CM9, which is restricted by the Mamu-
A01 MHC class I allele [18, 19], from peripheral blood of rhesus macaques at 3 and 20 WPV
using rhesus microarray. We found that gene expression profiles of Gag-specific CD8+ T cells
at 20 WPV are qualitatively different from those at 3 WPV. At 20 WPV, the most significant
transcriptional changes of Gag-specific CD8+ T cells were genes involved in cell TCR-signal-
ing, T cell differentiation and maturation toward central memory cells. Our study indicates
that a higher quality of SIV-specific CD8+ T cells elicited by SIVΔnef LAV over time contrib-
utes to the maturation of time-dependent protection.
Materials and methods
Ethics statement
Five adult female rhesus macaques (Macaca mulatta) of Indian origin were used in this longi-
tudinal study. and the macaques were housed in New England Primate Research Center
(NEPRC) in accordance with the regulations of the American Association of Accreditation of
Laboratory Animal Care and standards of the Association for Assessment and Accreditation
of Laboratory Animal Care International (AAALAC) as described previously [17]. The experi-
ments and procedures of this study were approved by Institutional Animal Care and Use Com-
mittee at Harvard Medical School (protocol 04383). All animals were housed in an AAALAC-
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accredited facility, and husbandry and care met the guidance of Animal Welfare Regulations
and standards in The Guide for the Care and Use of Laboratory Animals. All animals were
enrolled in the NEPRC behavioral management program, including an IACUC-approved plan
for Environmental Enrichment for research primates. Enrichment was provided through
manipulable devices, foraging opportunities, food items, structural and environmental
enhancements, and positive human interaction. Enrichment devices were rotated on a weekly
basis and included toys, mirrors, radios, TV/VCRs, foraging boards, and a variety of complex
foraging devices.
This protocol had an IACUC-approved exemption from social housing based on scientific
justification. Primary enclosures consisted of stainless steel primate caging provided by a com-
mercial vendor. Animal body weights and cage dimensions were regularly monitored. Overall
dimensions of primary enclosures (floor area and height) met the specifications of The Guide
for the Care and Use of Laboratory Animals, and the Animal Welfare Regulations (AWR).
Further, all primary enclosures were sanitized every 14 days at a minimum, in compliance
with AWRs. Secondary enclosures (room level) met specifications of The Guide with respect
to temperature, humidity, lighting and noise level. The animals were provided ad lib access to
municipal source water, offered commercial monkey chow twice daily, and offered fresh pro-
duce a minimum of three times weekly. Light cycle was controlled at 12/12 hours daily. The
animals were subject to twice daily including weekend documented observations by trained
animal care and veterinary staff. If signs of illness or distress were noted the veterinarians were
immediately notified. The animals were examined and supportive therapy given as required.
There were not any of the animals become severely ill or died at any time prior to the experi-
mental endpoint. To alleviate the non-human primates’ suffering, all invasive procedures were
performed after anesthesia. Euthanasia took place for all the animals at endpoints using proto-
cols consistent with the American Veterinary Medical Association (AVMA) guidelines. Ani-
mals were first sedated with intramuscular ketamine hydrochloride (20 mg/kg) followed by
sodium pentobarbital (100 mg/kg) intravenously to achieve euthanasia.
Vaccination and SIV-specific CD8+ T cell isolation
All 5 Mamu-A01 positive rhesus macaques were vaccinated intravenously with 20 ng of SIVΔ-
nef virus (supplied by Dr. Ronald Desrosiers) as described previously [14, 15]. APC-conju-
gated Mamu-A01 MHC class I tetramers complexed with the cognate SIV Gag181–189 epitope
(SIV Gag CM9 tetramers) [18] was kindly provided by Nancy Wilson and David Watkins
(Wisconsin National Primate Research Center, Madison, WI). Peripheral blood samples were
collected in EDTA tubes from vaccinated animals at week 3 (n = 5) and week 20 (n = 3) post-
vaccination. After isolation, peripheral blood mononuclear cells (PBMCs) were stained with
CM9 tetramer and anti-CD3 (SP34, FITC), anti-CD4 (L200, PerCP-Cy5.5) and anti-CD8
(RPA-T8, Alexa 700) antibodies. SIV Gag CM9 tetramer+ CD8+ T cells were sorted on a
FACS Aria II cell sorter (BD Biosciences) as reported previously [17]. Over 5×103 CM9-speci-
fic CD8+ T cells were yielded by sorting from each sample, with more than 99% purity.
Sample preparation and microarray hybridization
Total RNAs were extracted from sorted cells using TRIzol (Life Technologies), followed by
cDNA synthesis using Ovation Pico WTA System (Cat# 3300–12, NuGEN). After purification
with QIAquick PCR Purification Kit (Cat# 28104, QIAGEN), the cDNA samples were labeled
with biotin using Encore Biotin Module (Cat# 4200–12, NuGEN). All samples were assayed on
GeneChip Rhesus Macaque Genome Array (Cat# 900656, Affymetrix Inc.) in Genomics Core
Research Facility at University of Nebraska-Lincoln (UNL). The output files of microarray
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were deposited to the Gene Expression Omnibus (GEO) database under accession number
GSE75567.
Microarray data analysis
The data in CEL files from microarray assays were normalized using Robust Multi-array Anal-
ysis (RMA) correction algorithm, and Limma package [20] was then used for differential
expression analysis. Genes with fold change larger than 2 and P< 0.01 were defined as differ-
entially expressed genes (DEGs), which were further analyzed by ClueGO package of Cytos-
cape software [21] and literature search for gene function categories and pathway analysis.
Results
Different gene expression profiles of SIV Gag-specific CD8+ T cells at 20
versus 3 WPV
CD8+ T cells are thought to be critical for protecting against pathogenic SIV infection [22, 23].
However SIV-specific CD8+T cells elicited by SIVΔnef LAV are not quantitatively different
from CD8+ T cells of other vaccination strategies [24], and SIV-specific CD8+ T cells quantita-
tively and temporally did not correlate with maturation of immune protection [15], suggesting
that quality, rather than quantity, of SIV-specific CD8+ T cells may contribute to the time-
dependent protection induced by SIVΔnef vaccine [15]. Epitope mapping study showed that,
in rhesus macaques with Mamu-A01, Gag CM9 epitope (sequence: CTPYDINQM) of cyto-
toxic T lymphocytes (CTL) is immunodominant and plays an important role in controlling
SIV replication [18, 19].
To elucidate whether there are qualitative differences of gene expression in Gag-specific
CD8+ T cells at 3 and 20 WPV and whether these differences, if validated, temporally correlate
with emergence of protection, genome-wide transcriptional profiles were studied using rhesus
microarray. As shown in Fig 1A, there were differentially expressed genes (DEGs) at 20 WPV
Fig 1. Vaccination induced qualitative differences at week 20 compared with week 3. (A) Heat map of gene expression at 20
WPV compared with 3 WPV, shown as log2 (fold changes). Up-regulated and down-regulated genes are color-coded as red and
blue, respectively. (B). Histogram of number of up- and down-regulated genes at 20 WPV compared with 3 WPV.
https://doi.org/10.1371/journal.pone.0173929.g001
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as compared with 3 WPV. Of the total 788 DEGs at 20 WPV, 661 DEGs were up-regulated
(Fig 1B, S1 Table), demonstrating clear differences in gene expression in Gag-specific CD8+ T
cells from 3 to 20 WPV.
To gain insights into the functions of these DEGs, gene function analysis was performed
using ClueGO [21] and literature search. As shown in Fig 2, in the context of CD8+ T cells, the
DEGs are involved in multiple functional categories, such as T cell function and differentia-
tion, cytokine production and signaling, immune effector process, apoptosis, and macromole-
cule metabolism.
Gag-specific CD8+ T cells at 20 WPV increased stimulatory/inhibitory
molecule ratio
As shown in Fig 2, DEGs are involved in T cell receptor signaling and T cell differentiation.
CD8+ T cells are primarily signaled through T cell receptor α (TCRA) and β (TCRB), by MHC
class I and peptide complex and through co-stimulatory molecule CD28 by CD80 (B7-1) and
CD86 (B7-2). CTLA-4, a CD28 competitor on T cell surfaces with higher binding affinity to
CD80 and CD86, serves as inhibitory molecule. As shown in Figs 2 and 3, the TCRA
(3.5-fold), TCRB (6.4-fold) and CD28 (5.3-fold) were up-regulated at week 20 WPV, while
CTLA-4 had 4.3-fold down-regulation. This pattern suggests that the Gag-specific CD8+ T
cells were more functional at 20 WPV compared with 3 WPV. Down-regulation of Socs3, a
protein that facilitates T cell exhaustion, also suggested improved T-cell functionality at 20
WPV.
Besides the up-regulation of stimulatory gene expression and down-regulation of inhibitory
gene expression, the Gag-specific CD8+ T cells at 20 WPV also up-regulated MHC class II
genes HLA-DPB1 (5.6-fold), HLA-DQB1 (3.6-fold), and CD74 (2.7-fold).
Fig 2. Categories of differentially expressed genes. Up-regulated and down-regulated genes are colored as red and blue, respectively.
https://doi.org/10.1371/journal.pone.0173929.g002
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Gag-specific CD8+ T cells at 20 WPV down-regulated effector molecule
expression, and showed central memory properties as compared with 3
WPV
The Gag-specific CD8+ T cells at 20 WPV displayed an overall down-regulation of genes
involved in effector functions as compared with 3 WPV. As shown in Fig 2, the Gag-specific
CD8+ T cells at 20 WPV had lower expression of interferon-γ (IFNG, -5.3-fold), granzyme A
(GZMA, -3.2-fold), granzyme B (GZMB, -4.3-fold), and CCL5/RANTES (-2.9-fold), but had
elevated central memory functions, manifested by up-regulated expression of EOMES, IL-15,
CCR7, BATF, and down-regulated expression of RORA, which regulates CD8+ T cell activa-
tion and effector functions (Figs 2 and 3 and S1 Table). Memory CD8+ T cells express higher
level of EOMES [25], which is essential for long-term memory formation and homeostatic
renewal [26]. Up-regulated IL-15 may also help maintain longevity of memory CD8+ T cells
[27], and increased CCR7 expression may help CD8+ home to T cell zone in the secondary
lymphoid tissues. Furthermore, it was reported that while naive and antigen-specific effector
memory CD8+ T cells have CCR5+CCR7- and CCR5-CCR7+ phenotypes, antigen-specific
and less differentiated memory CD8+ T cells have CCR5+CCR7+ phenotype[28, 29]. The
Gag-specific CD8+ T cells at 20 WPV upregulated both CCR7 (5.6-fold) and CCR5 (2.4-fold).
Of note, Gag-specific CD8+ T cells at 20 WPV also upregulated CXCR5 (3.9-fold), which may
help some of Gag-specific CD8+ cells home to B follicles in the secondary lymphoid tissues.
Fig 3. Schematic representative of phenotypes of Gag-specific CD8+ T cells at 20 WPV. Up-regulated
and down-regulated genes are colored as red and blue, respectively.
https://doi.org/10.1371/journal.pone.0173929.g003
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Discussion
The Nef protein plays important roles in HIV-1/SIV pathogenesis in vivo, although it is not
required for viral replication in vitro[30]. Individuals infected with HIV-1 with defective nef
are associated with slow disease progression [31], and the pathogenicity of SIV after deleting of
nef is significantly attenuated in vivo in rhesus macaques. SIVΔnef live attenuated vaccine
(LAV) induces potent protection against subsequent intravenous challenge with pathogenic
wild-type SIVmac251 in a time-dependent manner from limited protection at 5 WPV to
potent protection at 15 WPV and thereafter [6, 17]. Previous studies demonstrated that SIV-
specific CD8+ T cells elicited by SIVΔnef vaccine contribute to the time-dependent protection
[2, 9–12]. Recently we found that IgG antibodies against SIV gp41 trimers correlated spatially
and temporally with the maturation of local protection against high-dose pathogenic SIV vagi-
nal challenge [14]. However, the quantity and location of Gag-specific CD8+ T cells in female
genital and lymphoid tissues induced by SIVΔnef vaccine do not correlate with protection
against vaginal challenge [15]. Billingsley and colleagues found that the transcriptional factor
profiles of SIV-specific CD8+ T cells after SIVΔnef vaccine changed over time and temporally
associated with protection, indicating SIV-specific CD8+ T cells elicited by SIVΔnef may be
qualitatively different between time points at which protection is and is not observed [17].
To further characterize the Gag-specific CD8+ T cells at the time points of protection and
no/limited protection, in this study, the global gene expression patterns of Gag-specific CD8
+ T cells at 3 and 20 WPV were compared. Our data showed that Gag-specific CD8+ T cells at
20 WPV have more central memory-like properties: higher expression of CCR7, EOMES, IL-
15, and lower effector gene expression as discussed above. After infection, antigen-specific
CD8+ T cells undergo clonal expansion and differentiate into effector memory T cells that
control the infection, while a small percentage of antigen-specific CD8+ T cells differentiate
into central memory T cells with lower killing ability but higher proliferation capacity [32].
After encountering the original pathogen, central memory CD8+ T cells mount stronger and
quicker responses, thus central memory CD8+ T cells can greatly contribute to recall responses
to control infection [33]. Our results are consistent with the results of a recent study of SIVΔ-
nef-induced Gag-specific CD8+ T cells [17] and another study showing that most of HIV-spe-
cific CD8+ T cells from elite controllers (EC) have central memory phenotype [34]. Central
memory CD8+ T cells, although existing at low frequencies in EC, have strong proliferative
capacity and efficiently control HIV-1 replication [34]. The up-regulated CCR7 expression in
central memory CD8+ T cells facilitates homing to secondary lymphoid tissues, where, upon
exposure to antigen again, they can be stimulated to proliferate and differentiate for virus con-
trol. In addition, our results showed that the Gag-specific CD8+ T cells also up-regulated che-
mokine receptor CXCR5 (3.9-fold). Recent studies indicated that antigen-specific CD8+ T
cells that express CXCR5 can migrate into B cell follicles of the secondary lymphoid tissues
[35–37]. Therefore it is plausible to speculate that the up-regulated expression of CXCR5 in
Gag-specific CD8+ T cells may reflect a subset of Gag-specific CD8+ T cells induced by the
SIVΔnef vaccine can home to B cell follicles.
Our results also show that, compared with week 3, Gag-specific CD8+ T cells at week 20 are
more functional, with up-regulated genes involved in T cell receptor signaling (TRA and TRB)
and co-stimulation (CD28). CD28-B7 interaction is necessary for generating class I major
histocompatibility complex-specific CTL[35]. It has been demonstrated that lack of CD28
expression on HIV-specific CD8+ T cells is associated with fast disease progression [36, 37].
CTLA-4 is a key negative regulator for T cell function and exerts inhibitory effects by compet-
ing with CD28 for ligands CD80 and CD86. It was reported that CTLA-4 blockade induces
tumor regression in several murine model [38, 39] and in patients with metastatic melanoma
Transcriptome profiles of Gag-specific CD8+ T cells elicited by SIVΔnef live attenuated vaccine
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in clinical trial [40, 41]. CTLA-4 blockade was also associated with decreased SIV RNA levels
in lymph nodes and an increase in the effector function of SIV-specific CD8+ T cells in rhesus
macaques [42]. The up-regulation of CD28 (5.3 fold) and down-regulation of CTLA-4 (-4.3
fold) suggest that Gag-specific CD8+ T cells at 20 WPV are more functional. In addition, com-
pared with CD8+ T cells from 3 WPV, the Gag-specific CD8+ T cells at 20 WPV also showed
lower levels of granzyme A and B expression. Delivery of granzyme A and B to target cells
results in an efficient elimination of CD4+ T cells infected with HIV-1 [43]. Because of lower
titer of SIVΔnef virus and less infected cells in vaccinated macaques at 20 WPV than 3 WPV, it
is plausible that the effector molecule granzyme A and B had lower expression. Consistent
with our observation, a study in influenza virus showed that, compared with acute infection,
GZMA and GZMB mRNA level decreased more than 2-fold in memory CD8+ T cells [44].
Interestingly, granzyme K (GZMK) was up-regulated at 20 WPV. Granzyme K expresses at
much lower level than granzyme A, but with higher specificity [45]. GZMA and GZMB defi-
cient mice can still launch effective and rapid killing of target cells, and the retained cytotoxic-
ity may because expression of GZMK [46]. And the roles of up-regulated GZMK in these Gag-
specific CD8+ T cells induced by SIVΔnef vaccine need further investigation.
Overall, this study shows that Gag-specific CD8+ T cells at week 20 are qualitatively differ-
ent from cells at week 3, and have properties of central memory T cells. The high level expres-
sion of CCR7, CXCR5 and other chemokine receptors in SIV-specific CD8+ T cells may direct
these cells trafficking to lymphoid tissues, and even to B follicles. And up-regulated expression
of genes involved in T cell signaling, especially up-regulation of CD28 and down-regulation of
CTLA-4, may render these cells functionally more capable, resulting in efficient control of sub-
sequent pathogenic SIV infection by quickly eliminating infected cells. Collectively, our study
indicates that a higher quality of SIV-specific CD8+ T cells elicited by SIVΔnef LAV over time
contributes to the maturation of time-dependent protection.
Supporting information
S1 Table. List of differentially expressed genes at 20 WPV compared with 3 WPV.
(XLSX)
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